Valuation
- Market cap
- 97,219,000
- Revenue TTM
- $78,230,000
- Net income TTM
- $-21,540,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -27.53%
- Debt to equity
- -2.07
Trading
- Volume
- 860,900
- Avg volume
- 132,444
- Day's range
- $9.48 – $9.72
- Shares out
- 10,127,000
- Stochastic %K
- 61%
- Beta
- -0.88
- Analysts
- Moderate Buy
- Price target
- $17.99
Company profile
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III cl...
Show more
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 267 364 3500
- Website
- https://www.optinose.com
- Address
- 777 Township Line Road, Suite 300, Yardley, United States
Latest news
No headlines yet.
